Is There a Role for Biweekly Romiplostim in the Management of Chronic Immune Thrombocytopenia (ITP)? A Report of Three Cases

Romiplostim is a peptibody, which stimulates platelet production by a mechanism similar to that of endogenous thrombopoietin. It has an established indication as second-line therapy in patients with chronic immune thrombocytopenia (ITP). The agent is typically administered weekly; however, there are...

Descripción completa

Detalles Bibliográficos
Autores principales: Rooprai, Jasjit Kaur, Khamisa, Karima
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247720/
https://www.ncbi.nlm.nih.gov/pubmed/30524761
http://dx.doi.org/10.1155/2018/6037494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247720/
https://www.ncbi.nlm.nih.gov/pubmed/30524761
http://dx.doi.org/10.1155/2018/6037494

Ejemplares similares